WO2000023089A1 - Formulation naturelle pour le traitement et la prevention de la depression et contenant st. john's wort et des derives de l'acide dihydro- et tetrahydrofolique - Google Patents

Formulation naturelle pour le traitement et la prevention de la depression et contenant st. john's wort et des derives de l'acide dihydro- et tetrahydrofolique Download PDF

Info

Publication number
WO2000023089A1
WO2000023089A1 PCT/EP1999/007556 EP9907556W WO0023089A1 WO 2000023089 A1 WO2000023089 A1 WO 2000023089A1 EP 9907556 W EP9907556 W EP 9907556W WO 0023089 A1 WO0023089 A1 WO 0023089A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
wort
john
formulation according
depression
Prior art date
Application number
PCT/EP1999/007556
Other languages
English (en)
Inventor
Herwig Buchholz
Angela Dudda
Jerzy Meduski
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to EP99950676A priority Critical patent/EP1121139A1/fr
Priority to US09/807,401 priority patent/US7014865B1/en
Priority to JP2000576863A priority patent/JP2002527484A/ja
Priority to CA002348693A priority patent/CA2348693C/fr
Publication of WO2000023089A1 publication Critical patent/WO2000023089A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to novel compositions containing a combination of the plant St. John's Wort (Hypericum perforatum L) and derivatives of folic acid.
  • This natural formulation is useful for the treatment and prevention of depression with a better effect than the ingredient compounds alone.
  • Depression is an increasingly common psychiatric disorder, affecting a large part of the population, especially in developed countries.
  • Modern standard pharmacological antidepression agents can be divided into several major groups: selective serotonin reuptake inhibitors, tricyclic and other heterocyclic antidepressants, monoamine oxidase (MAO) inhibitors, etc. 20 All of them provoke a wide range of adverse effects - from undesirable psy- chostimulation to hypertension and cardiotoxicity.
  • selective serotonin reuptake inhibitors tricyclic and other heterocyclic antidepressants
  • MAO monoamine oxidase
  • St. John's Wort is a perennial flowering plant that has been traditionally used in folk medicine for thousands of years due to its anti-inflammatory, analgesic
  • SJW The mechanism of action of SJW is not completely defined.
  • amentoflavone biapigenin, hyperforin, hypericin, hyperosid, pseudohypericin, quercetin and rutin (see Buter, B. et al., 1998, Planta Med. 64, 5, 431-437).
  • one active compound from SJW is a strong inhibitor of catechol-O-methyltransferase (see Mueller, W.E.G. et al., 1994, J. Geriatr. Psychiatr. Neurol. 7(Suppl. 1), 63-64; Mueller, W.E.G., 1995, Neuelichtechnisch, Lichtwer Pharma GmbH, Berlin) and monoamine oxidases (see Suzuki, O. et al., 1984, Planta Med. 50, 272-274). Monoamine oxidases participate in the breakdown of neurotransmitters serotonin and noradrenalin (see Perovic, S. et al., 1995, Arzn. Forsch/Drug Res. 45, 1145- 1148).
  • the biochemical mechanisms by which folic acid derivatives affect the neuro- psychiatric status apparently involve transmethylation reactions with components (DNA, RNA, proteins, biomembranes) of the central nervous system.
  • the methyl group from folate in the form of active metabolite 5- methyltetrahydrofolic acid, 5-MTHF, or 5-formyitetrahydrofolic acid, after be- ing reduced to 5-MTHF) is transferred to homocysteine to form methionine.
  • the de novo synthesis of methionine requires vitamin B12, since it involves a reaction catalyzed by vitamin B12-dependent methionine synthetase.
  • Methionine then participates in the reaction producing S-adenosylmethionine which is an important intermediate in more than 35 transmethylation reactions in CNS (see Bottiglieri, T. et al., 1994, Drugs 48, 137-152).
  • reactions relevant to the effect of folate level on depression is the synthesis of tetrahy- drobiopterin, a cofactor in the hydroxylation of phenylalanine and tryptophan playing a crucial role in the biosynthesis of the neurotransmitters dopamine, norepinephrine and serotonin.
  • the significant beneficial impact of the suggested composition on psychoneu- rological status is expected through a reduction of high levels of homocys- teine in the brain due to 5-methyl-tetrahydrofolic acid treatment.
  • High levels of homocysteine have been recognized as a major risk factor for a wide range of diseases including neurological and cerebrovascular diseases.
  • increased plasma homocysteine level has been linked to depression, mental and severe psychomotoric retardation.
  • MTHFR methylenetetrahydrofolate reductase
  • CS folic acid metabo- lism
  • the active metabolite in the folic acid pathway is 5-methyltetrahydrofolic acid which, orally administered, should be more efficacious than folic acid.
  • Folic acid given to the patients has to go through several reactions including a MTHFR catalyzed reaction to produce 5-methyltetrahydrofolic acid. All these steps can be by-passed with the direct introduction of 5-methyltetrahydrofolic acid. Of major importance is that 5-methyltetrahydrofolic acid is the only metabolite which is able to pass the blood-brain barrier.
  • St. John's Wort a traditional soft antide- pressant which improves the psychovegetative conditions by modulating the action of neurotransmitters
  • 5-methyltetrahydrofolic acid which improves the psychiatric condition by a reduction of the homocysteine concentration in the brain augment their beneficial effect when used in combination.
  • symptoms of depression are removed and also metabolic conditions of the central nervous system are improved. This leads to a decrease of intensity and frequency of attacks of depression.
  • the object of the present invention is an orally applicable natural formulation comprising St. John's Wort ⁇ Hype ⁇ cum perforatum) or its extracts or active ingredients in combination with folic acid derivatives or suitable salts thereof.
  • the St. John's Wort may be used as the whole plant, its water extract, etha- nol or any other extract. It is also possible to use just one or more of the plants ingredients. Especially preferred is the hypericin which is commercially available in different concentrations (e.g. 0.3% Hypericin St. John's Wort, Fa. Lichtwer, Berlin).
  • folic acid derivatives selected from the group consisting of 5-methyltetrahydrofolic acid, tetrahydrofoiic acid, dihydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10- methylentetrahydrofolic acid and 5-methenyltetrahydrofolic acid or their suitable salts are used.
  • 5-methyltetrahydrofolic acid or 5-formyltetrahydrofolic acid are especially preferred.
  • the folic acid derivatives may also be in the form of their salts.
  • vitamin B12 is a donor for methyl groups which are transferred by vitamin B12 to homocysteine.
  • Useful compositions may contain in one serving 400 to 5 000 meg of folic acid derivative and in case of 5-formyltetrahydrofolic acid 50 mg to 1 000 mg betaine and 0,5 to 10 meg vitamin B12.
  • the dose of St. John's Wort can be adjusted to the particular case in a wide range.
  • a commercially available extract of 0.3 % Hypericin is applied in an amount of 100 mg to 1000 mg.
  • the formulations according to the present invention may be prepared in form of tablets, gelcaps, capsules or syrups.
  • compositions of the present invention preferably are useful as food supplements, but they may also be administered in a pharmaceutical treatment.
  • the present invention makes available:
  • this invention provides an innovative formulation based on natural ingredients useful for the prevention and treatment of depression.
  • the combination of the natural compounds - St. John's Wort or its extracts or active ingredients and derivatives of dihydro- and tetrahydrofolic acid, derivatives thereof or corresponding salts - constitutes a unique and safe approach to the prevention and treatment of mild to moderate forms of depression without any side effects.
  • a lower dosed formulation according to the invention is obtained by mixing the following components:
  • a higher dosed formulation is obtained by mixing 600 mg of 0.3 % Hypericin St. John's Wort and 800 meg of 5-methyltetrahydrofolic acid calcium salt, formulated in gelcaps.
  • a formulation according to the invention is obtained by mixing 300 mg of 0,3 % Hypericin St. John's Wort, 400 meg of 5-formyltetrahydrofolic acid calcium salt, 300 mg betaine anhydrous and 3 meg vitamin B12 (cyanocobalamin), formulated in gelcaps.
  • a higher dosed formulation is obtained by mixing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur de nouvelles compositions contenant une combinaison de la plante St. John's Wort (Hypericum perforatum L.), ou des extraits ou des ingrédients actifs de celle-ci et des dérivés de l'acide dihydro- et tétrahydrofolique. Cette formulation naturelle est utile dans le traitement et la prévention de la dépression et présente un effet supérieur à celui des composés d'ingrédients seuls.
PCT/EP1999/007556 1998-10-19 1999-10-08 Formulation naturelle pour le traitement et la prevention de la depression et contenant st. john's wort et des derives de l'acide dihydro- et tetrahydrofolique WO2000023089A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99950676A EP1121139A1 (fr) 1998-10-19 1999-10-08 Formulation naturelle pour le traitement et la prevention de la depression et contenant st. john's wort et des derives de l'acide dihydro- et tetrahydrofolique
US09/807,401 US7014865B1 (en) 1998-10-19 1999-10-08 Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid
JP2000576863A JP2002527484A (ja) 1998-10-19 1999-10-08 セントジョーンズワートならびにジヒドロおよびテトラヒドロ葉酸の誘導体を含有する、うつ病の治療および予防のための天然製剤
CA002348693A CA2348693C (fr) 1998-10-19 1999-10-08 Formulation naturelle pour le traitement et la prevention de la depression et contenant st. john's wort et des derives de l'acide dihydro- et tetrahydrofolique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10471098P 1998-10-19 1998-10-19
US60/104,710 1998-10-19

Publications (1)

Publication Number Publication Date
WO2000023089A1 true WO2000023089A1 (fr) 2000-04-27

Family

ID=22301956

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007556 WO2000023089A1 (fr) 1998-10-19 1999-10-08 Formulation naturelle pour le traitement et la prevention de la depression et contenant st. john's wort et des derives de l'acide dihydro- et tetrahydrofolique

Country Status (4)

Country Link
EP (1) EP1121139A1 (fr)
JP (2) JP2002527484A (fr)
CA (1) CA2348693C (fr)
WO (1) WO2000023089A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534373A (ja) * 2000-06-02 2003-11-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 骨粗鬆症および／または炎症性関節疾患の処置および／または予防のための組成物
DE10315022A1 (de) * 2003-03-03 2004-09-23 Bioplanta Arzneimittel Gmbh Verwendung von Rutin und Isorhamnetin zur Behandlung von depressiven Verstimmungen und Erkrankungen sowie bei anderen affektiven Störungen
CN105687169A (zh) * 2016-03-18 2016-06-22 西北工业大学 金丝桃素作为胱硫醚β合成酶抑制剂在抗肿瘤方面的应用
WO2022040740A1 (fr) * 2020-08-25 2022-03-03 State of Mind Australasia Pty Ltd Méthode de traitement de la dépression et/ou de l'anxiété et/ou de leurs symptômes associés

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
JP6333136B2 (ja) * 2014-09-10 2018-05-30 サントリーホールディングス株式会社 セントジョーンズワート抽出物を含有する飲料

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820867A (en) * 1997-04-24 1998-10-13 Bewicke; Calverly M. General anti-depressant composition for dietary supplement
WO1999037155A1 (fr) * 1998-01-27 1999-07-29 Nutramax Laboratories, Inc. Combinaisons de tyrosine, d'agents de methylation, de phospholipides et de millepertuis pour le traitement de troubles mentaux

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229517B (it) * 1989-01-31 1991-09-03 Bioresearch Spa Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
FR2643081B1 (fr) * 1989-02-14 1991-06-07 Panmedica Sa Folates de magnesium, procede de preparation et compositions pharmaceutiques
US6096317A (en) * 1998-01-13 2000-08-01 Rexall Sundown St. John's Wort and methyl donor composition and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820867A (en) * 1997-04-24 1998-10-13 Bewicke; Calverly M. General anti-depressant composition for dietary supplement
WO1999037155A1 (fr) * 1998-01-27 1999-07-29 Nutramax Laboratories, Inc. Combinaisons de tyrosine, d'agents de methylation, de phospholipides et de millepertuis pour le traitement de troubles mentaux

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534373A (ja) * 2000-06-02 2003-11-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 骨粗鬆症および／または炎症性関節疾患の処置および／または予防のための組成物
DE10315022A1 (de) * 2003-03-03 2004-09-23 Bioplanta Arzneimittel Gmbh Verwendung von Rutin und Isorhamnetin zur Behandlung von depressiven Verstimmungen und Erkrankungen sowie bei anderen affektiven Störungen
CN105687169A (zh) * 2016-03-18 2016-06-22 西北工业大学 金丝桃素作为胱硫醚β合成酶抑制剂在抗肿瘤方面的应用
WO2022040740A1 (fr) * 2020-08-25 2022-03-03 State of Mind Australasia Pty Ltd Méthode de traitement de la dépression et/ou de l'anxiété et/ou de leurs symptômes associés

Also Published As

Publication number Publication date
JP2011132250A (ja) 2011-07-07
EP1121139A1 (fr) 2001-08-08
CA2348693A1 (fr) 2000-04-27
JP2002527484A (ja) 2002-08-27
CA2348693C (fr) 2008-07-15

Similar Documents

Publication Publication Date Title
US8815306B2 (en) Methods and compositions for promoting bone and joint health
ES2375302T3 (es) Derivados de ligustilida para el tratamiento de trastornos inflamatorios.
US10058529B2 (en) Nutraceutical composition for PDE4 inhibition, enhanced dopamine metabolism and long term potentiation
JP2011132250A (ja) セントジョーンズワートならびにジヒドロおよびテトラヒドロ葉酸の誘導体を含有する、うつ病の治療および予防のための天然製剤
Lv et al. Antidepressant activity of astilbin: involvement of monoaminergic neurotransmitters and BDNF signal pathway
Shrivastava et al. Therapeutic potential of Hypericum perforatum: a review
AU746072B2 (en) St. John's wort and methyl donor composition and uses thereof
US20080248106A1 (en) Melatonin-based composition for improved sleep
WO2019209229A2 (fr) Formulations topiques comprenant des extraits d'herbes
Krzysztoforska et al. Administration of protocatechuic acid affects memory and restores hippocampal and cortical serotonin turnover in rat model of oral D-galactose-induced memory impairment
Mullaicharam et al. St John's wort (Hypericum perforatum L.): A Review of its Chemistry, Pharmacology and Clinical properties
Kassis et al. Efficacy and safety assessments of Ferula assa-foetida L., traditionally used in Greco-Arab herbal medicine for enhancing male fertility, libido and erectile function
US7014865B1 (en) Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid
Mohammadipour A focus on natural products for preventing and cure of mitochondrial dysfunction in Parkinson’s disease
Nandy et al. Bacopa monnieri: The neuroprotective elixir from the East—Phytochemistry, pharmacology, and biotechnological improvement
Kumar et al. Neuroprotective effect of hesperidin and its combination with coenzyme Q10 on an animal model of ketamine-induced psychosis: behavioral changes, mitochondrial dysfunctions, and oxidative stress
Sánchez-Mateo et al. Hypericum grandifolium Choisy: a species native to Macaronesian Region with antidepressant effect
WO2020162859A2 (fr) Nouvelle combinaison contenant de la passiflore, de la glycine, du métylfolate et du thréonate de magnésium et son procédé de production
Anser et al. Comparison of the antidepressant like activity of homeopathic remedies (Argentum nitricum, Staphysagria and Ignatia amara) and their effect on the behavior of rodents.
US20130302419A1 (en) Use of a plant extract, pharmaceutical compositions and use thereof
Goud et al. Neuropharmacological Evaluation of Areca catechu on Chronic Unpredictable Mild Stress Model of Depression in Mice: Behavioral and Biochemical Evidences
Bhat Evaluation of Antidepressant Like Activity of Aqueous Extract of Fruits of Emblica Officinalis (AMLA) in Albino Mice
Mishra Bhagottar Gutika (Herbo-Mineral Formulation): An Overview
Audrey et al. Evaluation of the anti-inflammatory activity of a gel based on Afzelia africana (fabaceae) leaves
Lunenfeld et al. Modern antidepressants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1999950676

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09807401

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 576863

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2348693

Country of ref document: CA

Ref country code: CA

Ref document number: 2348693

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999950676

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1999950676

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999950676

Country of ref document: EP